Vaccines, Synthetic

JUL 30, 2026 · JOURNAL ARTICLE

Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience.

Human Vaccines & Immunotherapeutics

Single-center retrospective observational study of modest size with no control group, reporting feasibility and safety outcomes but lacking power to assess efficacy and generalizability.

JUL 9, 2026 · JOURNAL ARTICLE

T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2.

Human Vaccines & Immunotherapeutics

A mechanistic study using genetically modified mouse models demonstrating that T cell-associated immunity from a heterologous rBCG/protein vaccine confers cross-variant protection against SARS-CoV-2 JN.1, with clear immunological endpoints but limited to preclinical animal models.

JUN 16, 2026 · JOURNAL ARTICLE

Preventive and therapeutic efficacy of mRNA/LNP vaccines encoding HPV16 E6 and E7 in an early-intervention HPV tumor mouse models.

Human Vaccines & Immunotherapeutics

Preclinical murine tumor model study demonstrating HPV16 E7 mRNA/LNP vaccine efficacy in early-intervention setting, with no human data or comparator arm against standard therapy.